JP2020507624A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507624A5
JP2020507624A5 JP2019563696A JP2019563696A JP2020507624A5 JP 2020507624 A5 JP2020507624 A5 JP 2020507624A5 JP 2019563696 A JP2019563696 A JP 2019563696A JP 2019563696 A JP2019563696 A JP 2019563696A JP 2020507624 A5 JP2020507624 A5 JP 2020507624A5
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
independently
groups
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507624A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2018/050342 external-priority patent/WO2018146468A1/en
Publication of JP2020507624A publication Critical patent/JP2020507624A/ja
Publication of JP2020507624A5 publication Critical patent/JP2020507624A5/ja
Pending legal-status Critical Current

Links

JP2019563696A 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用 Pending JP2020507624A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
US62/455,645 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020507624A JP2020507624A (ja) 2020-03-12
JP2020507624A5 true JP2020507624A5 (enExample) 2021-03-11

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563696A Pending JP2020507624A (ja) 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用

Country Status (12)

Country Link
US (2) US11208384B2 (enExample)
EP (1) EP3580204A1 (enExample)
JP (1) JP2020507624A (enExample)
KR (1) KR20190115011A (enExample)
CN (1) CN110382465A (enExample)
AU (1) AU2018218518B2 (enExample)
BR (1) BR112019016258A2 (enExample)
CA (1) CA3051644A1 (enExample)
MA (1) MA47450A (enExample)
MX (1) MX2019009356A (enExample)
RU (1) RU2019127896A (enExample)
WO (1) WO2018146468A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
JP7229176B2 (ja) * 2017-02-07 2023-02-27 オブリーク セラピューティクス アーベー ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
EP3580204A1 (en) * 2017-02-07 2019-12-18 Oblique Therapeutics AB Sulfinylpyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47452A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
RU2020126540A (ru) * 2018-02-12 2022-03-14 Синда Фарма Аб Ингибиторы тиоредоксинредуктазы для применения для лечения рака

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031173B1 (en) 1979-12-19 1983-09-14 Duphar International Research B.V New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
EP0850223A1 (de) 1995-08-24 1998-07-01 Basf Aktiengesellschaft N-heterocyclische verbindungen, zwischenprodukte für ihre herstellung, sie enthaltende mittel und ihre verwendung zur bekämpfung von schadpilzen
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
JP2002507197A (ja) 1997-05-30 2002-03-05 ビーエーエスエフ アクチェンゲゼルシャフト 置換チオピリジン
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA92150C2 (ru) 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
CA2647338A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors-3
EP2061472A4 (en) * 2006-05-22 2010-12-22 Thioredoxin Systems Ab BACTERIAL THIOREDOXINE REDUCTASE INHIBITORS AND METHODS OF USING THE SAME
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
CA2763589A1 (en) 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
ES2608670T3 (es) 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
JP5850321B2 (ja) 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子NRSFに特異的に結合するmSin3Bに結合する化合物の利用
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
CA2864356A1 (en) 2012-02-10 2013-08-15 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by camp (epacs)
EP3019509B1 (en) 2013-07-10 2019-09-11 Boehringer Ingelheim International GmbH Novel chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
MA47452A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
EP3580204A1 (en) * 2017-02-07 2019-12-18 Oblique Therapeutics AB Sulfinylpyridines and their use in the treatment of cancer
JP7229176B2 (ja) 2017-02-07 2023-02-27 オブリーク セラピューティクス アーベー ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用

Similar Documents

Publication Publication Date Title
JP2020507624A5 (enExample)
JP2020506244A5 (enExample)
JP2020506970A5 (enExample)
JP2020533277A5 (enExample)
RU2019127896A (ru) Сульфинилпиридины и их применение при лечении рака
JP2019094345A5 (enExample)
CN110944997A (zh) Fxr受体激动剂
JP2010539110A5 (enExample)
CN110016025A (zh) 一种免疫调节剂
JP2019517487A5 (enExample)
JP2008546791A5 (enExample)
MX2014015158A (es) Derivados de piridinona y piridazinona.
RU2019128063A (ru) Углеводородсульфонилзамещенные пиридины и их применение при лечении рака
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2016523973A5 (enExample)
RU2015124002A (ru) Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
JP5855250B2 (ja) イミダゾオキサジン化合物による抗腫瘍効果増強剤
RU2018107879A (ru) Пиридины и их применение в лечении рака
JP2017522277A5 (enExample)
JP2016190843A5 (enExample)
JP2018529690A5 (enExample)
JP2019512535A5 (enExample)
JP2020527173A5 (enExample)
JP2019537602A5 (enExample)
JP2020507625A (ja) ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用